Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 17:10:1202696.
doi: 10.3389/fcvm.2023.1202696. eCollection 2023.

Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation

Fabrizio Salvucci  1 , Roberto Codella  2 , Adriana Coppola  3 , Irene Zacchei  4 , Gabriella Grassi  4 , Maria Luisa Anti  4 , Nicolita Nitisoara  1 , Livio Luzi  2   5 , Carmine Gazzaruso  2
Affiliations

Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation

Fabrizio Salvucci et al. Front Cardiovasc Med. .

Abstract

Introduction: Long-COVID is a broadly defined condition and there are no effective therapies. Cardiovascular manifestations of long-COVID include high heart rate, postural tachycardia, and palpitations. Previous studies have suggested that mast cell activation (MCA) may play a role in the pathophysiology of long-COVID, including in the mechanisms of its cardiovascular manifestations. The present study aimed to evaluate the effectiveness of a treatment with blockers of histamine receptors in patients with long-COVID who did not respond to other therapies.

Methods: In all, 14 patients (F/M = 9/5; 49.5 ± 11.5 years) and 13 controls (F/M = 8/5; 47.3 ± 8.0 years) with long-COVID symptoms attributed to MCA were evaluated. Patients were treated with fexofenadine (180 mg/day) and famotidine (40 mg/day). Fatigue, brain fog, abdominal disorders, and increased heart rate were evaluated in treated and untreated patients at baseline and 20 days later.

Results: Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms (improved or disappeared) in all treated patients, and the improvement grade was significantly greater in treated patients compared to controls. No significant differences in the outcomes were observed in the controls.

Conclusions: Our data confirm that histamine receptors blockade may be an effective target to successfully treat long-COVID. Our finding supports the underlying role of MCA in the pathophysiology of long-COVID.

Keywords: antihistamines; histamine receptors; long-COVID; mast cell activation; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Gazzaruso C, Carlo Stella N, Mariani G, Tamburlini A, Garini P, Freddi E, et al. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19. Clin Rheumatol. (2020) 39:2475–7. 10.1007/s10067-020-05239-5 - DOI - PMC - PubMed
    1. Pujia R, Ferro Y, Maurotti S, Khoory J, Gazzaruso C, Pujia A, et al. The effects of COVID-19 on the eating habits of children and adolescents in Italy: a pilot survey study. Nutrients. (2021) 13:2641. 10.3390/nu13082641 - DOI - PMC - PubMed
    1. Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID-mechanisms, risk factors, and management. Br Med J. (2021) 374:n1648. 10.1136/bmj.n1648 - DOI - PubMed
    1. Mayer N, Meza-Torres B, Okusi C, Delanerolle G, Chapman M, Wang W, et al. Developing a long COVID phenotype for post-acute COVID-19 in a national primary care sentinel cohort: an observational retrospective database analysis. JMIR Public Health Surveill. (2022). 8:e36989. 10.2196/36989 - DOI - PMC - PubMed
    1. Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. (2021) 32:e2315. 10.1002/rmv.2315 - DOI - PubMed

LinkOut - more resources